Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Common Equity: 2020-2025

Historic Common Equity for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $292.0 million.

  • Mirum Pharmaceuticals' Common Equity rose 25.87% to $292.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $292.0 million, marking a year-over-year increase of 25.87%. This contributed to the annual value of $225.6 million for FY2024, which is 9.26% down from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Common Equity is $292.0 million, which was up 14.46% from $255.2 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Common Equity high stood at $292.0 million for Q3 2025, and its period low was $56.4 million during Q3 2021.
  • For the 3-year period, Mirum Pharmaceuticals' Common Equity averaged around $221.7 million, with its median value being $233.3 million (2025).
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 53.10% in 2021, then soared by 200.19% in 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' Common Equity (Quarterly) stood at $120.2 million in 2021, then climbed by 18.16% to $142.0 million in 2022, then surged by 75.07% to $248.7 million in 2023, then decreased by 9.26% to $225.6 million in 2024, then grew by 25.87% to $292.0 million in 2025.
  • Its Common Equity stands at $292.0 million for Q3 2025, versus $255.2 million for Q2 2025 and $233.3 million for Q1 2025.